TG Therapeutics | TGTX - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 1000K 2026-06
Alaunos Therapeutics USD 1.01M 175K 2026-03
Amgen USD 11.69B 6.9B 2026-06
Ardelyx USD 127.27M 7.15M 2026-03
Arrowhead Research USD 245.35M 30.35M 2026-06
Bayer EUR 10.04B 168M 2026-06
Biogen USD 2.98B 1.02B 2026-06
Corcept Therapeutics USD 214.85M 343K 2026-06
Curis USD 11.52M 2.5M 2026-03
Gilead Sciences USD 3.95B 19.57B 2026-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Novartis USD 10.2B 912M 2026-06
Novavax USD 126.2M 23.62M 2025-12
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06
Verastem USD 63.57M 4.56M 2026-03
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06